穆勒错误:线性无值 (LNT) 剂量反应和美国环保署的癌症风险评估政策和实践
Edward J Calabrese1, Paul B Selby2
1School of Public Health and Health Sciences, Amherst, MA, 01003, USA; Department of Environmental Health Sciences, Amherst, MA, 01003, USA; Morrill I, N344, Amherst, MA, 01003, USA; University of Massachusetts, Amherst, MA, 01003, USA.
Chemico-biological interactions
|August 12, 2023
概括
这项研究揭示了赫尔曼·穆勒的六个概念错误,导致了癌症风险评估的线性无值 (LNT) 模型. 当代研究强调了这种广泛使用的LNT模型的显著局限性.
科学领域:
- 环境科学 环境科学
- 毒理学 毒理学 毒理学
- 辐射生物学 辐射生物学
背景情况:
- 赫尔曼·穆勒的工作对环境政策和风险评估实践产生了重大影响.
- 线性无值 (LNT) 模型历来在全球范围内用于癌症风险评估.
- 当前的科学理解质疑LNT模型的普遍适用性.
研究的目的:
- 识别和分析赫尔曼·穆勒作品中六个主要的概念科学错误.
- 解释这些错误是如何促进LNT剂量反应模型的发展的.
- 支持正在进行的研究,证明LNT模型在癌症风险评估中的局限性.
主要方法:
- 赫尔曼·穆勒的科学贡献和概念框架的历史分析.
- 审查LNT模型的基础原则和历史实施.
- 综合当代研究评估LNT模型的有效性和局限性.
主要成果:
- 在穆勒的作品中发现了六个关键的概念科学错误.
- 这些错误显然影响了LNT剂量反应模型的建立.
- 这篇论文提供了证据,支持LNT模型对风险评估的重大局限性.
结论:
- 穆勒的概念错误对环境和辐射风险政策产生了持久的影响,尽管有缺陷.
- 从这些错误中产生的LNT模型需要进行批判性重新评估,以准确评估癌症风险.
- 这项研究强调了需要更新的科学模型,更好地反映生物现实.
相关概念视频
Mutagenicity and Carcinogenicity
1.3K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.3K
Dose-Response Relationship: Overview
3.2K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
3.2K
Dose-Response Relationship: Potency and Efficacy
4.6K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.6K
Nonlinear Pharmacokinetics: Overview
434
Nonlinear or dose-dependent pharmacokinetics is a phenomenon that occurs when the pharmacokinetic parameters of certain drugs deviate from linear pharmacokinetics at higher doses. These drugs do not follow the expected first-order kinetics, where the rate of drug elimination is directly proportional to the drug concentration. Instead, they exhibit a nonlinear relationship, which can be attributed to several factors.
Nonlinearity can arise due to the saturation of plasma protein-binding or...
Nonlinearity can arise due to the saturation of plasma protein-binding or...
434
Drug Regulation
1.4K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.4K
Dose-Response Relationship: Selectivity and Specificity
7.0K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
7.0K


